{"id":1116,"date":"2017-12-05T11:23:01","date_gmt":"2017-12-05T16:23:01","guid":{"rendered":"http:\/\/carolinaurologicresearchcenter.com\/?page_id=1116"},"modified":"2024-03-13T21:32:54","modified_gmt":"2024-03-14T01:32:54","slug":"current-trials-bladder-cancer","status":"publish","type":"page","link":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/","title":{"rendered":"Bladder Cancer"},"content":{"rendered":"<div id='av_section_1'  class='avia-section av-5oecjw-389275f9ba43c645cc982b02afe5f05d main_color avia-section-default avia-no-border-styling  avia-builder-el-0  el_before_av_textblock  avia-builder-el-first  avia-bg-style-scroll container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-1116'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-4tanws-7e77434710894c784657dfdbd3827458\">\n.flex_column.av-4tanws-7e77434710894c784657dfdbd3827458{\nborder-radius:0px 0px 0px 0px;\npadding:0px 0px 0px 0px;\n}\n<\/style>\n<div  class='flex_column av-4tanws-7e77434710894c784657dfdbd3827458 av_one_full  avia-builder-el-1  avia-builder-el-no-sibling  first flex_column_div av-zero-column-padding  '     ><section  class='av_textblock_section av-ko31jgkm-9c6dbbe374b8b72ddb29ed29c2b7bfdc '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><div id=\"advanced_metastatic_uc\">\n<div id=\"advanced_metastatic_uc\">\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><strong><u>Low or Intermediate risk NMIBC<\/u><\/strong><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>JH Incyte<\/u><\/strong>\u2013 Phase 2 Window of Opportunity Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients with Recurrent Low-or Intermediate-Risk Tumors<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Pemigatinib<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 2023<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03914794?term=j18158&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT03914794<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>Janssen ErdaRIS<\/u><\/strong>\u2013 Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Erdafitinib Intravesical Delivery System<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: April 14, 2027<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05316155\" target=\"_blank\" rel=\"noopener\">NCT05316155<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><strong><u>Low Grade Upper Tract UC<\/u><\/strong><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>TOOKAD ENLIGHTENED<\/u><\/strong>\u2013 Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: padeliporfin<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: January 25, 2029<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT04620239\" target=\"_blank\" rel=\"noopener\">NCT04620239<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>High grade NMIBC BCG Na\u00efve or no BCG within 3 years<\/u><\/h2>\n<p><strong><span style=\"text-decoration: underline;\">SunRise-3<\/span>:<\/strong> <span style=\"color: #808080;\">A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in Participants With BCG-na\u00efve High-Risk Non-Muscle Invasive Bladder Cancer<\/span><\/p>\n<\/div>\n<div id=\"high_grade_nmibc\">\n<div id=\"advanced_metastatic_uc\">\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: TAR-200 (GermRIS) + Cetrelimab vs BCG, no BCG within 3 years&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 9, 2030<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05714202\" target=\"_blank\" rel=\"noopener\">NCT05714202<\/a><\/span><\/p>\n<\/div>\n<hr>\n<div id=\"high_grade_nmibc\">\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">PATAPSCO<\/span>: <\/strong>A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination with Durvalumab in Adult BCG-na\u00efve, High-risk Non\u2013Muscle-Invasive Bladder Cancer Participants&nbsp;<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Durva + BCG (induction + maintenance), no BCG within 3 years&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 30, 2027<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05943106\" target=\"_blank\" rel=\"noopener\">NCT05943106<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>High Grade NMIBC Post BCG<\/u><\/h2>\n<\/div>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Theralase<\/span>: <\/strong>A study of intravesical photodynamic therapy for BCG-unresponsive NMIBC patients&nbsp;<span style=\"text-decoration: underline;\">WITH CIS<\/span><\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: TLD-1433 Bladder Infusion + Photodynamic Therapy<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 2022<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03945162\" target=\"_blank\" rel=\"noopener\">NCT03945162<\/a><\/span><\/p>\n<hr>\n<\/div>\n<p id=\"high_grade_nmibc\">&nbsp;<\/p>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">MK057<\/span>: <\/strong>A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination With Other Investigational Agents in Subjects With High Risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: cohort C: Vibostolimab\/Pembro vs Favezelimab\/Pembro for persistent or recurrent <u>CIS<\/u> post BCG&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: August 31, 2030<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02625961\" target=\"_blank\" rel=\"noopener\">NCT02625961<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">CG BOND<\/span>: <\/strong>A Phase 3, Randomized Study of Adjuvant&nbsp;<mark class=\"hl-term\">Cretostimogene<\/mark>&nbsp;Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: cohort P: intravesical cretostimogene for BCG unresponsive NMIBC without CIS <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: January 2030<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06111235\" target=\"_blank\" rel=\"noopener\">NCT06111235<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>Low Grade or IR or High Grade NMIBC BCG <\/u><u>Na\u00efve\/no BCG within 2 years or post BCG<\/u><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Aura<\/span>: <\/strong>A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intramural injection with or without intratumoral injection in subjects with non-muscle invasive bladder cancer (NMIBC)<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: intramural injection w\/wo intratumoral injection of AU-011 (belzupacap sarotalocan); cohort 1a: intramural injection then RC, cohort 1b: intramural &amp; intratumoral injection then TURBT, cohort 2: intramural injection + laser then TURBT, cohort 3: intramural injection + laser then RC, cohort 4: intramural &amp; intratumoral injection + laser then TURBT <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: July 2024<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05483868\" target=\"_blank\" rel=\"noopener\">NCT05483868<\/a><\/span><\/p>\n<hr>\n<p><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Luminos<\/span>:<\/strong> A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1\/\u200bL1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors<\/span><span style=\"color: #808080;\">Phase: 1\/2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: intravesical PVSRIPO, BCG na\u00efve or post BCG (adequate or not), no BCG within 3 months&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 2025<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT04690699\" target=\"_blank\" rel=\"noopener\">NCT04690699<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>Intermediate Risk NMIBC<\/u><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>PIVOT<\/u>:&nbsp; <\/strong>A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: CG0070 (I+M) after TURBT vs observation after TURBT&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: January 2030<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT06111235\" target=\"_blank\" rel=\"noopener\">NCT06111235<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>High Grade NMIBC BCG Na\u00efve\/no BCG within 2 years or post BCG<\/u><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Protara TARA-002<\/span>: <\/strong>A Phase 1a\/b, dose finding, open-label study to evaluate safety and toxicity, of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: dose finding of intravesical TARA-002 for <u>CIS<\/u> unable to receive BCG or received at least one dose of BCG or intravesical chemo<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 2023<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05085977\" target=\"_blank\" rel=\"noopener\">NCT05085977<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">enGene<\/span>: <\/strong>A Phase 1\/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Na\u00efve or Received Incomplete BCG Treatment<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1\/2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: intravesical EG-70 (non-viral gene therapy) <u>CIS<\/u>, cohort 1: post BCG, cohort 2: BCG na\u00efve or incomplete BCG <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: February 2026<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT04752722\" target=\"_blank\" rel=\"noopener\">NCT04752722<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">SURGEtx<\/span>: <\/strong>A Phase 1\/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1\/2a<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: intramural injection STM-416 after TURBT<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: September 2024<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05710848\" target=\"_blank\" rel=\"noopener\">NCT05710848<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>Intermediate Risk or High Grade NMIBC post BCG<\/u><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">PROKARIUM<\/span>: <\/strong>A Phase 1\/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: phase 1 ZH9 (microbial IO) oral priming + intravesical, post BCG or BCG intolerable &amp; post 1L intravescial tx <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: May 30, 2027<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT06181266\" target=\"_blank\" rel=\"noopener\">NCT06181266<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>MIBC<\/u><\/h2>\n<p><span style=\"color: #808080;\"><strong><em>Bladder Sparing<\/em><\/strong><\/span><\/p>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">KEYNOTE-992<\/span>: <\/strong>Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-<span class=\"hit_inf\">992<\/span>\/<span class=\"hit_inf\">KEYNOTE-992<\/span>)<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Pembrolizumab with Chemoradiotherapy (CRT) vs. CRT Alone<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: February 10, 2027<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04241185?term=keynote+992&amp;cntry=US&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT04241185<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Janssen BLC3001<\/span>:&nbsp;<\/strong>A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: TAR-200 plus Cetrelimab vs. CRT<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: December 15, 2028<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04658862?term=17000139blc3001&amp;draw=2&amp;rank=1\" target=\"_blank\" rel=\"noopener\">NCT04658862<\/a><\/span><\/p>\n<hr>\n<p><span style=\"color: #808080;\"><strong><em>Radical Cystectomy<\/em><\/strong><\/span><\/p>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">KEYNOTE-905<\/span>:&nbsp;<\/strong>Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 3<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Pembrolizumab with Radical Cystectomy plus Pelvic Lymph Node Dissection vs. Radical Cystectomy plus Pelvic Lymph Node Dissection<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: February 16, 2026<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03924895\">NCT03924895<\/a><\/span><\/p>\n<hr>\n<div id=\"high_grade_nmibc\">\n<\/div>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Janssen BLC2002<\/span>: <\/strong>A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 2<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: neoadjuvant TAR-200 (GemRIS) + Cetrelimab + RC vs Cetrelimab + RC for cisplatin-ineligible\/refusal <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: December 17, 2025<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT04919512\" target=\"_blank\" rel=\"noopener\">NCT04919512<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>Janssen ErdaRIS<\/u><\/strong>\u2013 Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: Erdafitinib intravesical (TAR-210) FGFR+, cohort 4: MIBC scheduled for RC and cisplatin-refusal\/ineligible <\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: April 14, 2027<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05316155\" target=\"_blank\" rel=\"noopener\">NCT05316155<\/a><\/span><\/p>\n<hr>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Aura<\/span>: <\/strong>A Phase 1, open-label trial of belzupacap sarotalocan (AU-011) to determine the feasibility and safety of intramural injection with or without intratumoral injection in subjects with non-muscle invasive bladder cancer (NMIBC)<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: cohort 5: intratumoral injection of AU-011 (bel-sar) + laser then RC<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: July 2024<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05483868\" target=\"_blank\" rel=\"noopener\">NCT05483868<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>Locally Advanced or Metastatic UC<\/u><\/h2>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><u>LOXO-FG3:<\/u> <\/strong>An Open-Label, Multicenter Study of&nbsp;<span class=\"hit_org\">LOXO-435<\/span>&nbsp;(LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations<\/span><\/p>\n<p><span style=\"color: #808080;\">Phase: 1a\/b<\/span><br \/>\n<span style=\"color: #808080;\">Study Product: dose-escalation of LOXO-435 (FGFR3 inhibitor) + Pembro for FGFR3+ mUC&nbsp;<\/span><br \/>\n<span style=\"color: #808080;\">Estimated Study Completion Date: June 2025<\/span><br \/>\n<span style=\"color: #808080;\">ClinicalTrials.gov Identifier:&nbsp;<a style=\"color: #808080;\" href=\"https:\/\/clinicaltrials.gov\/show\/NCT05614739\" target=\"_blank\" rel=\"noopener\">NCT05614739<\/a><\/span><\/p>\n<hr>\n<h2 data-fontsize=\"22\" data-lineheight=\"27\"><u>RCC<\/u><\/h2>\n<p><span style=\"color: #808080;\"><strong><em>Locally Advanced or Metastatic &#8211; treatment&nbsp;<\/em><\/strong><\/span><span style=\"color: #808080;\"><b><i>na\u00efve<\/i><\/b><\/span><\/p>\n<p data-fontsize=\"20\" data-lineheight=\"24\"><span style=\"color: #808080;\"><strong><span style=\"text-decoration: underline;\">Exelixis Stellar-002 expansion<\/span>:&nbsp;<\/strong><\/span><\/p>\n<p><span style=\"color: #808080;\">Study Product: cohort 6: nccRCC- Arm 1: XL092 vs Arm 2: XL092 + Nivo (must have measurable disease)&nbsp;<\/span><\/p>\n<hr>\n<p><span style=\"color: #808080;\">Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.<\/span><\/p>\n<p><strong><span style=\"color: #808080;\">Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.<\/span><br \/>\n<\/strong><\/p>\n<\/div>\n<div id=\"high_grade_nmibc\">&nbsp;<\/div>\n<\/div><\/section><\/div><\/div><\/div><\/main><!-- close content main element --><\/div><\/div><div id='after_section_1'  class='main_color av_default_container_wrap container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-1116'><div class='entry-content-wrapper clearfix'><section  class='av_textblock_section av-2036sc-a61ae4a36c1f6087cacabbf31d818215 '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><h3><span style=\"color: #18629b;\">Please fill in the form below to email us to learn more about our trials:<\/span><\/h3>\n<script type=\"text\/javascript\">var gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,initializeOnLoaded:function(o){gform.domLoaded&&gform.scriptsLoaded?o():!gform.domLoaded&&gform.scriptsLoaded?window.addEventListener(\"DOMContentLoaded\",o):document.addEventListener(\"gform_main_scripts_loaded\",o)},hooks:{action:{},filter:{}},addAction:function(o,n,r,t){gform.addHook(\"action\",o,n,r,t)},addFilter:function(o,n,r,t){gform.addHook(\"filter\",o,n,r,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,n){gform.removeHook(\"action\",o,n)},removeFilter:function(o,n,r){gform.removeHook(\"filter\",o,n,r)},addHook:function(o,n,r,t,i){null==gform.hooks[o][n]&&(gform.hooks[o][n]=[]);var e=gform.hooks[o][n];null==i&&(i=n+\"_\"+e.length),gform.hooks[o][n].push({tag:i,callable:r,priority:t=null==t?10:t})},doHook:function(n,o,r){var t;if(r=Array.prototype.slice.call(r,1),null!=gform.hooks[n][o]&&((o=gform.hooks[n][o]).sort(function(o,n){return o.priority-n.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==n?t.apply(null,r):r[0]=t.apply(null,r)})),\"filter\"==n)return r[0]},removeHook:function(o,n,t,i){var r;null!=gform.hooks[o][n]&&(r=(r=gform.hooks[o][n]).filter(function(o,n,r){return!!(null!=i&&i!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][n]=r)}});<\/script>\n                <div class='gf_browser_opera gform_wrapper gform_legacy_markup_wrapper gform-theme--no-framework' data-form-theme='legacy' data-form-index='0' id='gform_wrapper_3' ><div id='gf_3' class='gform_anchor' tabindex='-1'><\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_3' id='gform_3'  action='\/wp-json\/wp\/v2\/pages\/1116#gf_3' data-formid='3' novalidate>\n                        <div class='gform-body gform_body'><ul id='gform_fields_3' class='gform_fields top_label form_sublabel_below description_below'><li id=\"field_3_8\" class=\"gfield gfield--type-name gfield_contains_required field_sublabel_below gfield--no-description field_description_below gfield_visibility_visible\"  data-js-reload=\"field_3_8\" ><label class='gfield_label gform-field-label gfield_label_before_complex' >Name:<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_complex ginput_container ginput_container--name no_prefix has_first_name no_middle_name has_last_name no_suffix gf_name_has_2 ginput_container_name gform-grid-row' id='input_3_8'>\n                            <span id='input_3_8_3_container' class='name_first gform-grid-col' >\n                                                    <input type='text' name='input_8.3' id='input_3_8_3' value=''   aria-required='true'    \/>\n                                                    <label for='input_3_8_3' class='gform-field-label gform-field-label--type-sub '>First<\/label>\n                                               <\/span>\n                            <span id='input_3_8_6_container' class='name_last gform-grid-col' >\n                                                    <input type='text' name='input_8.6' id='input_3_8_6' value=''   aria-required='true'    \/>\n                                                    <label for='input_3_8_6' class='gform-field-label gform-field-label--type-sub '>Last<\/label>\n                                                <\/span>\n                            <div class='gf_clear gf_clear_complex'><\/div>\n                        <\/div><\/li><li id=\"field_3_6\" class=\"gfield gfield--type-email gfield_contains_required field_sublabel_below gfield--no-description field_description_below gfield_visibility_visible\"  data-js-reload=\"field_3_6\" ><label class='gfield_label gform-field-label' for='input_3_6'>Email:<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_6' id='input_3_6' type='email' value='' class='large'    aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/li><li id=\"field_3_7\" class=\"gfield gfield--type-phone gfield_contains_required field_sublabel_below gfield--no-description field_description_below gfield_visibility_visible\"  data-js-reload=\"field_3_7\" ><label class='gfield_label gform-field-label' for='input_3_7'>Phone:<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_phone'><input name='input_7' id='input_3_7' type='tel' value='' class='medium'   aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/li><li id=\"field_3_2\" class=\"gfield gfield--type-radio gfield--type-choice gfield_contains_required field_sublabel_below gfield--no-description field_description_below gfield_visibility_visible\"  data-js-reload=\"field_3_2\" ><label class='gfield_label gform-field-label' >Are you a patient of either Atlantic Urology Clinics or Carolina Urologic Research Center?<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_radio'><ul class='gfield_radio' id='input_3_2'>\n\t\t\t<li class='gchoice gchoice_3_2_0'>\n\t\t\t\t<input name='input_2' type='radio' value='Yes'  id='choice_3_2_0'    \/>\n\t\t\t\t<label for='choice_3_2_0' id='label_3_2_0' class='gform-field-label gform-field-label--type-inline'>Yes<\/label>\n\t\t\t<\/li>\n\t\t\t<li class='gchoice gchoice_3_2_1'>\n\t\t\t\t<input name='input_2' type='radio' value='No'  id='choice_3_2_1'    \/>\n\t\t\t\t<label for='choice_3_2_1' id='label_3_2_1' class='gform-field-label gform-field-label--type-inline'>No<\/label>\n\t\t\t<\/li><\/ul><\/div><\/li><li id=\"field_3_4\" class=\"gfield gfield--type-textarea gfield_contains_required field_sublabel_below gfield--no-description field_description_below gfield_visibility_visible\"  data-js-reload=\"field_3_4\" ><label class='gfield_label gform-field-label' for='input_3_4'>My question is:<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_textarea'><textarea name='input_4' id='input_3_4' class='textarea medium'     aria-required=\"true\" aria-invalid=\"false\"   rows='10' cols='50'><\/textarea><\/div><\/li><\/ul><\/div>\n        <div class='gform_footer top_label'> <input type='submit' id='gform_submit_button_3' class='gform_button button' value='Submit'  onclick='if(window[\"gf_submitting_3\"]){return false;}  if( !jQuery(\"#gform_3\")[0].checkValidity || jQuery(\"#gform_3\")[0].checkValidity()){window[\"gf_submitting_3\"]=true;}  ' onkeypress='if( event.keyCode == 13 ){ if(window[\"gf_submitting_3\"]){return false;} if( !jQuery(\"#gform_3\")[0].checkValidity || jQuery(\"#gform_3\")[0].checkValidity()){window[\"gf_submitting_3\"]=true;}  jQuery(\"#gform_3\").trigger(\"submit\",[true]); }' \/> <input type='hidden' name='gform_ajax' value='form_id=3&amp;title=&amp;description=&amp;tabindex=0&amp;theme=legacy' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_3' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='3' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_3' value='WyJbXSIsImQyNWE2ODVkMzRmNGQxOWQ1MjZiMTIyYmQ2ODE4YTVmIl0=' \/>\n            <input type='hidden' class='gform_hidden' name='gform_target_page_number_3' id='gform_target_page_number_3' value='0' \/>\n            <input type='hidden' class='gform_hidden' name='gform_source_page_number_3' id='gform_source_page_number_3' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <p style=\"display: none !important;\" class=\"akismet-fields-container\" data-prefix=\"ak_\"><label>&#916;<textarea name=\"ak_hp_textarea\" cols=\"45\" rows=\"8\" maxlength=\"100\"><\/textarea><\/label><input type=\"hidden\" id=\"ak_js_1\" name=\"ak_js\" value=\"9\"\/><script>document.getElementById( \"ak_js_1\" ).setAttribute( \"value\", ( new Date() ).getTime() );<\/script><\/p><\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_3' id='gform_ajax_frame_3' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 3, 'https:\/\/carolinaurologicresearchcenter.com\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', true );jQuery('#gform_ajax_frame_3').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_3');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_3').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_3').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_3').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_3').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_3').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_3').val();gformInitSpinner( 3, 'https:\/\/carolinaurologicresearchcenter.com\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', true );jQuery(document).trigger('gform_page_loaded', [3, current_page]);window['gf_submitting_3'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}setTimeout(function(){jQuery('#gform_wrapper_3').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_3').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [3]);window['gf_submitting_3'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_3').text());}, 50);}else{jQuery('#gform_3').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"3\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);                if (event.defaultPrevented) {                return;         }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_3\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_3\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_3\" );        let postRenderFired = false;                function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            jQuery( document ).trigger( 'gform_post_render', [3, current_page] );            gform.utils.trigger( { event: 'gform\/postRender', native: false, data: { formId: 3, currentPage: current_page } } );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\n<\/div><\/section><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":27,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC<\/title>\n<meta name=\"description\" content=\"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"og:description\" content=\"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Carolina Urologic Research Center - Myrtle Beach, SC\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-14T01:32:54+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/\",\"name\":\"Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC\",\"isPartOf\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\"},\"datePublished\":\"2017-12-05T16:23:01+00:00\",\"dateModified\":\"2024-03-14T01:32:54+00:00\",\"description\":\"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/carolinaurologicresearchcenter.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Current Trials\",\"item\":\"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bladder Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/carolinaurologicresearchcenter.com\/#website\",\"url\":\"https:\/\/carolinaurologicresearchcenter.com\/\",\"name\":\"Carolina Urologic Research Center - Myrtle Beach, SC\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","description":"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","og_description":"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.","og_url":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/","og_site_name":"Carolina Urologic Research Center - Myrtle Beach, SC","article_modified_time":"2024-03-14T01:32:54+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/","url":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/","name":"Bladder Cancer - Carolina Urologic Research Center - Myrtle Beach, SC","isPartOf":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/#website"},"datePublished":"2017-12-05T16:23:01+00:00","dateModified":"2024-03-14T01:32:54+00:00","description":"Current patient trials for bladder cancer and patient studies for bladder cancer. Contact us to determine your eligibility for patient trials.","breadcrumb":{"@id":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/current-trials-bladder-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/carolinaurologicresearchcenter.com\/"},{"@type":"ListItem","position":2,"name":"Current Trials","item":"https:\/\/carolinaurologicresearchcenter.com\/current-trials\/"},{"@type":"ListItem","position":3,"name":"Bladder Cancer"}]},{"@type":"WebSite","@id":"https:\/\/carolinaurologicresearchcenter.com\/#website","url":"https:\/\/carolinaurologicresearchcenter.com\/","name":"Carolina Urologic Research Center - Myrtle Beach, SC","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/carolinaurologicresearchcenter.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/pages\/1116"}],"collection":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/comments?post=1116"}],"version-history":[{"count":13,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/pages\/1116\/revisions"}],"predecessor-version":[{"id":2047,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/pages\/1116\/revisions\/2047"}],"up":[{"embeddable":true,"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/pages\/27"}],"wp:attachment":[{"href":"https:\/\/carolinaurologicresearchcenter.com\/wp-json\/wp\/v2\/media?parent=1116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}